Skip to content

Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.

Prospective Study of Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation Admitted to an Intensive Care Unit.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03090581
Enrollment
132
Registered
2017-03-27
Start date
2017-03-15
Completion date
2018-03-31
Last updated
2017-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Transplant Rejection

Keywords

Graft Rejection/diagnosis, Lung Transplantation, Cryoprobe

Brief summary

The survival of lung transplant patients (PD) is limited mainly by Infections, graft dysfunction in the immediate postoperative period and chronic dysfunction. Up to 36% have an episode of acute rejection after transplantation. For the diagnosis of these pathologies, transbronchial lung biopsy (BPTB) is essential. The classical method is the realization of BPTB with conventional clamp, but the performance diagnosis is limited. However, the use of cryoprobes for sampling in other pulmonary pathologies have been shown to achieve a higher diagnostic yield. The BPTB performance is variable and depends on factors such as sample size and the presence of artifacts (crushing) produced by the forceps tweezers. The objective principal is to compare the diagnostic yield of samples obtained with cryoprobe compared to those obtained with conventional biopsy tweezers. A prospective, randomized, and comparative study is proposed for all patients in the intensive care unit after lung transplantation in a 24-month period, at Vall de Hebron Hospital. Patients will be divided into two groups: symptomatic and asymptomatic. The exclusion criteria are the contraindications of the procedure and the factors which increase the hemorrhagic risk. A flexible bronchoscope (BF-18BS) will be used and the procedure will be performed according to the technique conventional. The patient undergoing the procedure will be intubated, sedated and relaxed under supervision and continuous monitoring by an intensivist. A bronchoalveolar lavage and a maximum of 6 samples will be obtained. Morphological study (middle area, artifacts, components, diagnosis), microbiological, histological and anatomopathological according to the usual protocol. The duration of the procedure, the complications and the frequency with which the diagnosis obtained after the procedure modifies the therapeutic behavior will be monitored. These data will allow to evaluate the potential benefits of this procedure in the diagnosis of pulmonary pathology in lung transplantation.

Detailed description

Bronchoscopic examinations will be performed with intubated patients under continuous monitoring (pulse oximetry, blood pressure, heart and respiratory rate), Oxygen therapy with high flows and surveillance by anesthesiologist. The bronchopulmonary lobe where the biopsies will be performed is determined prior to the procedure based on an imaging study (chest x-ray or computed tomography). Transbronchial biopsies will be obtained using a flexible bronchoscope (Pentax, 3.2 mm working channel), which approaches the subsegment where the affected area is located. The 2.4 mm diameter cryoprobe is placed (Erbokryo®), and moves forward until it encounters a soft resistance. The cryoprobe is removed between 5-10 mm and the freezing is applied for 3 seconds. After 3 seconds, the probe is gently removed together with the bronchoscope and frozen tissue sample at the tip of the probe. In the case of strong resistance, the process is stopped and then repeated. In the case of the use of forceps, the conventional technique is used.

Interventions

PROCEDUREBiopsies CP

Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.

PROCEDUREBiopsies FC

Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.

Sponsors

Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

A prospective, randomized, comparative study in all patients.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pulmonary transplant patients admitted to the intensive care unit who are assigned a transbronchial lung biopsy.

Exclusion criteria

* Respiratory insufficiency refractory to oxygen therapy. * Acute or subacute ischemic heart disease. * Severe arrhythmias. * Coagulation disorders: platelets \< 60,000-50,000 or Prothrombin time \> 60%. * Lack of informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients in whom a pathological diagnosis is obtained after obtaining transbronchial biopsies, performed with forceps or cryosondes.5 days after biopsiesGraft rejection is classified according to the criteria of the International Society for Heart and Lung Transplantation (ISHLT) in 2007.

Secondary

MeasureTime frameDescription
Number of alveoli, bronchioles, bronchi, blood vessels and pleura containing each biopsy.5 days after biopsiesA microscope will be used with Software Mese. ¨Leica Application Suite X¨.
Number of complications related to the procedure.30 days after biopsiesComplications: bleeding, pneumothorax, infection or acute respiratory failure.

Countries

Spain

Contacts

Primary ContactKarina I Loor, MD
kloor@vhebron.net93 274 6138
Backup ContactJavier De Gracia, MD PhD
jgracia.jgracia@gmail.com93 274 6138

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026